



Short Communication

Alpha-1 antitrypsin gene polymorphism in Chronic Obstructive Pulmonary Disease (COPD)

Sabri Denden^{1*}, Amel Haj Khelil^{1*}, Jalel Knani², Ramzi Lakhdar¹, Pascale Perrin³, Gérard Lefranc⁴ and Jemni Ben Chibani¹

¹Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, Monastir, Tunisia.

²Pulmonology Department, CHU Tahar Sfar, Mahdia, Tunisia.

³Institute of Evolution Sciences, University of Montpellier-II, France.

⁴Institute of Human Genetics, University of Montpellier-II, France.

Abstract

Alpha-1-antitrypsin (AAT) plays an important role in the pathogenesis of emphysema, the pathological lesion underlying the majority of the manifestations of Chronic Obstructive Pulmonary Disease (COPD). In this study we tested the hypothesis that common AAT polymorphisms influence the risk of developing COPDs. We investigated PiM1 (Ala213Val), PiM2 (Arg101His), PiM3 (Glu376Asp), PiS (Glu264Val) and PiZ (Glu342Lys) *SERPINA1* alleles in 100 COPD patients and 200 healthy controls. No significant differences were observed in allele frequencies between COPD patients and controls, neither did haplotype analysis show significant differences between the two groups. A cross-sectional study revealed no significant relationship between common *SERPINA1* polymorphisms (PiM1, PiM2, PiM3) and the emphysematous type of COPD. In addition, FEV₁ annual decline, determined during a two-year follow up period, revealed no difference among carriers of the tested polymorphisms.

Key words: alpha-1 antitrypsin, *SERPINA1* polymorphisms, COPD, emphysema, lung function.

Received: January 16, 2009; Accepted: September 9, 2009.

Chronic obstructive pulmonary disease (COPD), a heterogeneous disorder, is a major cause of respiratory disability and the fourth major cause of death world-wide (World Health Organization, 2000). Exposure to cigarette smoke is recognized as the main environmental risk factor involved (Teramoto, 2007). Severe Alpha-1-antitrypsin deficiency (AATD) is a proven genetic risk factor, with about 80% of the subjects develop the disease between 30 to 40 years or earlier, in spite of only 1%-3% of COPD cases being due to severe AAT deficiency (Lomas and Silverman, 2001).

Alpha-1 antitrypsin (AAT) is a 52 kDa protein synthesized primarily by hepatocytes. Its main function is to inhibit the activity of neutrophil elastase in the lung. This is a protease capable of destroying the major structural proteins of the alveolar wall. Plasma AAT deficiency results in accelerated elastin degradation, leading to a loss of ventilator function and the subsequent development of emphysema (Mahadeva and Lomas, 1998). The AAT coding gene *SERPINA1* is highly polymorphic, with more than 125 SNPs reported in public databases, its most common alleles

being the normal M alleles and its subtypes (PiM1Ala, PiM1Val, PiM2, PiM3), besides the deficient alleles PiS and PiZ (Crystal, 1990). About 95% of the individuals with severe AATD are homozygous for PiZt (ATS/ERS, 2003), whereas PiSZ heterozygotes have approximately one-third of the normal AAT serum level, besides being highly prone to the development of diseases (Dahl *et al.*, 2005). COPD risk among PiMZ heterozygotes has been previously analyzed with controversial results. Meta-analysis indicates a slight increase in risk of COPD in PiMZ individuals, with no significant lung-function impairment, compared to PiMM (Hersh *et al.*, 2004).

A few studies on *SERPINA1* common variants in COPD have been reported, also with controversial results. Matsuse *et al.* (1995), Shim (2001) and Kim *et al.* (2005) did not find a significant association between PiM1, PiM2 or PiM3 alleles and COPD, whereas Kwok *et al.* (2004) came across a significant increase in PiM1M3, PiM2M3 phenotypes and Gupta *et al.* (2005) reported a significant increase for the PiM3 allele in COPD patients.

For a better understanding of the association between *SERPINA1* polymorphisms and COPD risk, we designed a case-control study to detect differences in the frequencies of common SNP alleles, haplotypes and genotypes, be-

Send correspondence to Denden Sabri. Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, 1, AV. Avicenne 5019, Monastir, Tunisia. E-mail: denden_sabri@yahoo.fr.

*These authors contributed equally to this work.

tween patients and controls in relation to common polymorphisms.

We also investigated the relationship between common *SERPINA1* polymorphisms and main COPD clinical manifestations. The major AAT neutrophil elastase inhibitory role is observed in alveolar parenchyma, the subsequent deficiency in plasma AAT concentration mainly resulting in emphysema (Needham and Stockley, 2004). We therefore compared the distribution of *SERPINA1* polymorphisms between the bronchial and emphysematous types of COPD. In addition, COPD patients underwent a two-year follow up, in order to evaluate the annual FEV₁ (Forced Expiratory Volume in 1 s) decline rate in relation to common *SERPINA1* alleles. FEV₁ is the hallmark of COPD since it is affected by inflammation and remodeling of the small airways as well as by emphysematous destruction of the terminal airspaces (Weiss *et al.*, 2003).

The study population consisted of 100 COPD subjects who attended the Pneumology Department of Tahar Sfar Hospital in Mahdia. Inclusion criteria for patients with COPD were as follows: FEV₁ < 80% of predicted value adjusted for age, weight and height, and an improvement in FEV₁ following bronchodilator inhalation < 12% of baseline FEV₁. Asthmatic patients showing a persistent airflow obstruction were excluded. COPD phenotype identification was based on chest radiographic and high-resolution computerized tomography (HRCT) density findings. Clinical characteristics of COPD patients are summarized in Table S1. Follow-up examinations were conducted with patients over a two-year period after baseline, with annually repeated spirometry tests. AATD individuals were excluded from analysis. Two hundred healthy controls were enrolled for the case-control study. They were recruited from a blood donor's cohort of Fattouma Bourguiba Hospital in Monastir. Subjects with respiratory diseases, or any family history of lung disease, were excluded. The distribution of both patients and controls, according to demographic characteristics, is shown in Table S2. Prior written informed consent was obtained from all the subjects according to the research protocol approved by the local ethics committee.

Total genomic DNA was extracted from peripheral blood leucocytes by a phenol-chloroform method. PCR-RFLP was employed for genotyping of PiM1 (Ala213 GCG → Val GTG), PiS (Glu264 GAA → Val GTA) and PiZ (Glu342 GAG → Lys AAG) polymorphisms, as previously described (Ferrarotti *et al.*, 2004). Briefly, we performed PCR amplification using exon III primers to detect the S and 213Ala/Val variants and exon V for the Z variant. The reactions were carried out in an I-cycler Thermal Cycler (Bio-Rad Laboratories). 4 U of *SexA1* and *Hpy99I* restriction enzymes (New England Biolabs) were used to digest 4 μL each of exon III and exon V amplified DNA, respectively. Genotyping of PiM2 (Arg101 CGT → His CAT) and PiM3 (Glu376 GAA → Asp GAC) was performed using hybridization probe analysis on Light Cycler

480 Roche apparatus (Roche Diagnostics), using a commercial real-time assay (LightMix[®], Roche Diagnostics). For each SNP, the primers flanking the SNP and the oligonucleotide probes were designed and synthesized by the manufacturer. The reaction mixture was prepared in a 96-well PCR plate and processed according to manufacturer's instructions. Real-time PCR cycling conditions were as follows: 95 °C for 5 min, followed by 35 cycles of 95 °C for 10 s, 62 °C for 15 s and 72 °C for 15 s. After amplification, PCR products were analyzed in a melting step of 40-95 °C. Melting data were analyzed using the Genescanning module of the LightCycler 480 software.

Annual FEV1 decline (ml/year) was calculated as the difference between follow-up and baseline observed FEV1 values, divided by the number of months between the two surveys, and multiplied by 12. SPSS v.10.0 software was used for statistical analysis. Categorical variables were presented as percentages, and intergroup differences were compared using χ^2 test or Fisher's exact tests. Continuous variables, described as mean \pm standard deviation, were compared between the groups using Student's t test. Hardy Weinberg equilibrium tests and the estimation of allele and haplotype frequencies were performed using HPlus v. 2.5 software.

The frequency of PiM1, PiM2, PiM3, PiS and PiZ alleles and genotypes between COPD patients and healthy controls, was determined and compared (Table 1). Genotypes for all the polymorphisms were within Hardy-Weinberg proportions. There was no significant difference in the genotypic and allelic distribution of normal PiM1, PiM2 and PiM3 variants between subjects and controls. Deficient PiS and PiZ alleles were only reported in patients, with no apparent significant difference in relation to controls. Ten haplotypes were selected for studying by the expectation maximization procedure (Table 2), with no significant differences being detected between patients and controls by statistical comparison.

COPD patients were classified according to their predominant phenotype as follows: 53 subjects showed the bronchial type of the disease (chronic bronchitis group; mean age: 72.1 \pm 7.6 years); 47 presented a predominant parenchymal destructive change (centrolobular and panlobular emphysema groups; mean age: 69.5 \pm 12.2 years). Univariate analysis was employed to verify whether there were differences in COPD phenotypes among *SERPINA1* genotypes (M1Ala containing vs. non M1Ala containing; M2 containing vs. non M2 containing and M3 containing vs. non M3 containing). The relationship between FEV₁ annual decline, smoking and BMI and COPD phenotypes was also examined. No significant differences were detected (Table 3).

Lung function impairment in patients was assessed by the annual FEV₁ decline rate. After exclusion of AAT deficient individuals, 96 patients underwent a two-year follow up Annual FEV₁ decline means were compared according

Table 1 - *SERPINA1* genotypes and alleles in COPD patients and controls.

	Genotype			Allele		HWE p
Ala213Val	CC	CT	TT	C	T	
Controls	0.63	0.33	0.04	0.79	0.21	0.699 ^a
Patients	0.63	0.31	0.06	0.78	0.22	0.418 ^a
p	0.764 ^a	0.887 ^a	0.516 ^a		0.671 ^a	
OR (95% CI)					1.096 (0.718-1.672)	
Arg101His	GG	GA	AA	G	A	
Controls	0.57	0.38	0.05	0.77	0.23	0.440 ^a
Patients	0.61	0.36	0.03	0.78	0.22	0.380 ^a
p	0.862 ^a	0.937 ^a	0.477 ^b		0.770 ^a	
OR (95% CI)					0.939 (0.617-1.430)	
Glu376Asp	AA	AC	CC	A	C	
Controls	0.49	0.45	0.06	0.73	0.28	0.217 ^a
Patients	0.53	0.39	0.08	0.73	0.27	0.648 ^a
p	0.348 ^a	0.413 ^a	0.497 ^a		0.798 ^a	
OR (95% CI)					0.951 (0.645-1.402)	
Glu264Val	AA	AT	TT	A	T	
Controls	1	0	0	1	0	N/A
Patients	0.98	0.02	0	0.99	0.01	0.917 ^a
p	0.193 ^b	0.193 ^b	N/A		0.193 ^b	
OR (95% CI)					10.199 (0.487-213.501)	
Glu342Lys	GG	GA	AA	G	A	
Controls	1	0	0	1	0	N/A
Patients	0.98	0.02	0	0.99	0.01	0.917 ^a
p	0.193 ^b	0.193 ^b	N/A		0.193 ^b	
OR (95% CI)					10.199 (0.487-213.501)	

HWE: Hardy-Weinberg Equilibrium. ^aPearson's χ^2 test; ^bFisher's exact test.

Table 2 - *SERPINA1* SNP haplotypes in COPD patients and controls.

Haplotype ^a	Patients	Controls	p ^b	OR	95% CI
GTAGA	0.48265	0.48773	1	1	N/A
GCAGA	0.21581	0.20572	0.864	1.04	0.67-1.61
ATAGC	0.18798	0.20385	0.683	0.91	0.56-1.46
GTAGC	0.08046	0.07999	0.974	0.99	0.50-1.96
ATAGA	0.01730	0.02270	0.663	0.77	0.24-2.50
ATTGA	0.00526	0.00000	N/A	N/A	N/A
ATAAC	0.00524	0.00000	N/A	N/A	N/A
GCAAA	0.00524	0.00000	N/A	N/A	N/A
GTAAC	0.00005	0.00000	N/A	N/A	N/A
ACAGC	0.00001	0.00000	N/A	N/A	N/A

^aHaplotype frequency determined using expectation maximization method; ^bFisher's exact test.

to age, smoking habits and *SERPINA1* polymorphisms. No significant relationship between annual FEV₁ decline and the tested variables was detected (Table 4).

In summary, our findings are consistent with observations that there is no significant difference in the frequency of common *SERPINA1* variants in COPD patients, when

Table 3 - Association studies of bronchial and emphysematous COPD types with annual FEV₁ decline (Δ FEV₁), cigarette smoking, body mass index (BMI) and *SERPINA1* genotypes.

Type/Class	COPD phenotype		p
	CB	CLE+PEL	
Δ FEV ₁ (ml/year)	171 ± 137	232 ± 239	0.243 ^a
Cumulative cigarette consumption	59.41 ± 29.22	51.97 ± 28.68	0.230 ^a
BMI (kg/m ²)	24.33 ± 3.70	22.77 ± 5.21	0.117 ^a
M1Ala	0.41	0.53	
No M1Ala	0.58	0.47	0.306 ^b
M2	0.45	0.45	
No M2	0.54	0.54	1 ^b
M3	0.39	0.53	
No M3	0.60	0.46	0.184 ^b

CB: Chronic Bronchitis; CLE: Centrolobular Emphysema; PEL: Panlobular Emphysema; Cumulative cigarette consumption = number of packs smoked per day multiplied by years of consumption. M1Ala: heterozygous and homozygous for Ala213 allele; no M1Ala: homozygous for Val213 allele; M2: heterozygous and homozygous for His101 allele; no M2: homozygous for Arg101 allele; M3: heterozygous and homozygous for Asp376 allele; no M3: homozygous for Glu376 allele.

^aStudent's t test; ^bPearson's χ^2 test.

Table 4 - Association studies of lung function impairment with smoking, body mass index (BMI), age and *SERPINA1* genotypes.

Type/class	Δ FEV ₁ (mL/year)	p ^a
Smoking status		
Never	151 ± 131	
Smoker	197 ± 191	0.683
Cumulative cigarette consumption		
< mean	164 ± 179	
> mean	230 ± 194	0.197
BMI (kg/m ²)		
< mean BMI	221 ± 239	
> mean BMI	178 ± 144	0.408
Age		
< mean age	165 ± 109	
> mean age	207 ± 211	0.455
M1Ala	195 ± 177	
No M1Ala	194 ± 205	0.983 ^a
M2	195 ± 156	
No M2	195 ± 204	0.999
M3	205 ± 212	
No M3	187 ± 152	0.726

Cumulative cigarette consumption = number of packs smoked per day multiplied by years of consumption. M1Ala: heterozygous and homozygous for Ala213 allele; no M1Ala: homozygous for Val213 allele; M2: heterozygous and homozygous for His101 allele; no M2: homozygous for Arg101 allele; M3: heterozygous and homozygous for Asp376 allele; no M3: homozygous for Glu376 allele.

^aStudent's t test.

compared to healthy controls. We also verified that there is no correlation between these alleles and the manifestation of emphysema, since there was no difference in their distribution in patients with bronchial and emphysematous types of COPD. Furthermore, no significant relationship between *SERPINA1* polymorphisms and annual FEV₁ decline evaluated over a two-year period in COPD patients was found. To our knowledge, this is the first report on clinical manifestations of COPD in relation to common AAT variants.

Acknowledgments

This work was supported by a grant from the Ministry of Education and Scientific Research in Tunisia.

References

- ATS/ERS Statement (2003) Standards for the diagnosis and management of individuals with alpha-1 Antitrypsin deficiency. Lung disease section. *Am J Respir Crit Care Med* 168:823-849.
- Crystal RG (1990) α 1-antitrypsin deficiency, emphysema, and liver disease genetic basis and strategies for therapy. *J Clin Invest* 85:1343-1352.
- Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK and Nordestgaard BG (2005) The protease inhibitor PI*S allele and COPD: A meta-analysis. *Eur Respir J* 26:67-76.

Ferrarotti I, Zorzetto M, Scabini R, Mazzola P, Campo I and Luisetti M (2004) A novel method for rapid genotypic identification of alpha1-antitrypsin variants. *Diagn Mol Pathol* 12:160-163.

Gupta J, Bhadoria DP, Lal MK, Kukreti R, Chattopadhyaya D, Gupta VK, Dabur R, Yadav V, Chhillar AK and Sharma GL (2005) Association of the PIM3 allele of the alpha-1-antitrypsin gene with chronic obstructive pulmonary disease. *Clin Biochem* 38:489-491.

Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG and Silverman EK (2004) Chronic obstructive pulmonary disease in alpha 1-antitrypsin PI MZ heterozygotes: A meta-analysis. *Thorax* 59:843-849.

Kim CH, Yim JJ, You CG, Lee CT, Kim YW, Han SK and Shim YS (2005) Alpha-antitrypsin genotypes in Korean patients with chronic obstructive pulmonary disease. *Respirology* 10:223-228.

Kwok JSY, Lawton JWM, Yew WW, Chau CH, Lee J and Wong PC (2004). Protease inhibitor phenotypes and serum alpha-1-antitrypsin levels in patients with COPD: A study from Hong Kong. *Respirology* 9:265-270.

Lomas DA and Silverman EK (2001) The genetics of chronic obstructive pulmonary disease. *Respir Res* 2:20-26.

Mahadeva R and Lomas DA (1998) Genetics and respiratory disease* 2: Alpha 1 antitrypsin deficiency, cirrhosis and emphysema. *Thorax* 53:501-505.

Matsuse T, Fukuchi Y, Matsui H, Sudo E, Nagase T and Orimo H (1995) Effect of cigarette smoking on pulmonary function in each phenotype M of α -1-Protease inhibitor*. *Chest* 107:395-400.

Needham M and Stockley RA (2004) α 1-antitrypsin deficiency * 3: Clinical manifestations and natural history. *Thorax* 59:441-445.

Shim YS (2001) Epidemiological survey of chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency in Korea. *Respirology* 6:S9-S11.

Teramoto S (2007) 1. COPD pathogenesis from the viewpoint of risk factors. *Intern Med* 46:77-79.

Weiss ST, DeMeo DL and Postma DS (2003) COPD: Problems in diagnosis and measurement. *Eur Respir J* 21:4s-12s.

Internet Resources

HPlus software v 2.5, <http://qge.fhrc.org/hplus> (June 18, 2007).
World Health Organization (2000) the World Health Report 2000, <http://www.who.int/whr/2000/en/> (December 3, 2008).

Supplementary Material

The following online material is available for this article:

- Table S1 - Clinical characteristics of COPD patients at baseline.

- Table S2 - Demographic characteristics of COPD patients and healthy controls

This material is made available as part of the on-line article from <http://www.scielo.br.gmb>.

Associate Editor: Francisco Mauro Salzano

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table S1 - Clinical characteristics of COPD patients at baseline.

Clinical characteristics	COPD Patients (n = 100)
COPD phenotype	
CB	52%
CB+CLE	35%
PLE	13%
Spirometry	
FEV ₁	1.16 ± 0.61
FEV ₁ % pred	41.7 ± 16.8
FVC	1.55 ± 0.78
FVC % pred	43.7 ± 18.5
RV %	2.7 ± 3.4
Blood gases	
PaO ₂	69.2 ± 10.6
PaCO ₂	43.2 ± 10
SaO ₂	93 ± 3.8
COPD stage	
I	2%
II	24%
III	48%
IV	26%

CB: Chronic Bronchitis; CLE: Centrolobular Emphysema; PLE: Panlobular Emphysema; FEV₁: Forced Expiratory Volume in 1 s (L); FVC: Forced Vital Capacity (L); FEV₁ % pred: percentage of the predicted FEV₁ value adjusted to age, height and weight. FVC % pred: percentage of the forecast FVC value adjusted to age, height and weight. RV: Reversibility of baseline FEV₁ following bronchodilator inhalation; PaO₂: arterial oxygen partial pressure (mm Hg); PaCO₂: arterial carbon monoxide partial pressure (mm Hg); SaO₂: Arterial oxygen saturation (%).

Table S2 - Demographic characteristics of COPD patients and healthy controls.

Demographic characteristics	COPD patient (n = 100)	Controls (n = 200)	p
Age	69.45 ± 12.34	43.86 ± 8.97	0.00 ^a
male:female	98:2	189:11	0.15 ^b
BMI	24.5 ± 4.0	24.4 ± 2.9	0.80 ^a
Smoking status			
Never	7	16	
Ex	52	89	
Current	41	95	0.09 ^b
Cumulative cigarette consumption	53.74 ± 29.76	48.41 ± 23.86	0.14 ^a
Geographic origin in Tunisia			
North	0	4	
Center	100	192	
South	0	4	0.08 ^b

BMI: Body mass index, weight (kg)/(height (m))². Cumulative cigarette consumption = number of packs smoked per day multiplied by years of consumption.

^aStudent's t test; ^bPearson's χ^2 test.